WO2014146139A3 - Srm assay to indicate cancer therapy - Google Patents

Srm assay to indicate cancer therapy Download PDF

Info

Publication number
WO2014146139A3
WO2014146139A3 PCT/US2014/031138 US2014031138W WO2014146139A3 WO 2014146139 A3 WO2014146139 A3 WO 2014146139A3 US 2014031138 W US2014031138 W US 2014031138W WO 2014146139 A3 WO2014146139 A3 WO 2014146139A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer therapy
indicate cancer
srm assay
fgfri
ret
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/031138
Other languages
French (fr)
Other versions
WO2014146139A2 (en
Inventor
David B. Krizman
Todd Hembrough
Sheeno Thyparambil
Wei-Li Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Expression Pathology Inc
Original Assignee
Expression Pathology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020187018431A priority Critical patent/KR20180080342A/en
Priority to AU2014232155A priority patent/AU2014232155B2/en
Priority to CN201480021231.9A priority patent/CN105229164B/en
Priority to KR1020157028737A priority patent/KR101874501B1/en
Priority to EP18210192.3A priority patent/EP3470513B1/en
Priority to EP18210194.9A priority patent/EP3474014B1/en
Priority to JP2016502614A priority patent/JP6412100B2/en
Priority to EP14763214.5A priority patent/EP2984176B1/en
Priority to CA2906965A priority patent/CA2906965C/en
Application filed by Expression Pathology Inc filed Critical Expression Pathology Inc
Priority to EP18210185.7A priority patent/EP3470845B1/en
Publication of WO2014146139A2 publication Critical patent/WO2014146139A2/en
Publication of WO2014146139A3 publication Critical patent/WO2014146139A3/en
Priority to US14/855,154 priority patent/US9840728B2/en
Anticipated expiration legal-status Critical
Priority to IL241631A priority patent/IL241631B/en
Priority to US15/837,888 priority patent/US20180195107A1/en
Priority to AU2018206787A priority patent/AU2018206787A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01045—Thymidylate synthase (2.1.1.45)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Electrochemistry (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the ALK, Ros, Ron, Ret, TS, and/or FGFRI proteins that are particularly advantageous for quantifying the ALK, Ros, Ron, Ret, TS, and/or FGFRI proteins directly in biological samples that have been fixed in formalin by the methods of Selected Reaction Monitoring (SRM) mass spectrometry, or as Multiple Reaction Monitoring (MRM) mass spectrometry.
PCT/US2014/031138 2013-03-15 2014-03-18 Srm assay to indicate cancer therapy Ceased WO2014146139A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA2906965A CA2906965C (en) 2013-03-15 2014-03-18 Srm assay to indicate cancer therapy
CN201480021231.9A CN105229164B (en) 2013-03-15 2014-03-18 SRM assays indicative of cancer therapy
EP18210185.7A EP3470845B1 (en) 2013-03-15 2014-03-18 Srm assay to indicate cancer therapy
EP18210192.3A EP3470513B1 (en) 2013-03-15 2014-03-18 Srm assay to indicate cancer therapy
EP18210194.9A EP3474014B1 (en) 2013-03-15 2014-03-18 Srm assay to indicate cancer therapy
JP2016502614A JP6412100B2 (en) 2013-03-15 2014-03-18 SRM assay to indicate cancer therapy
EP14763214.5A EP2984176B1 (en) 2013-03-15 2014-03-18 Srm assay to indicate cancer therapy
KR1020187018431A KR20180080342A (en) 2013-03-15 2014-03-18 SRM Assay to Indicate Cancer Therapy
KR1020157028737A KR101874501B1 (en) 2013-03-15 2014-03-18 SRM Assay to Indicate Cancer Therapy
AU2014232155A AU2014232155B2 (en) 2013-03-15 2014-03-18 SRM assay to indicate cancer therapy
US14/855,154 US9840728B2 (en) 2013-03-15 2015-09-15 SRM assay to indicate cancer therapy
IL241631A IL241631B (en) 2013-03-15 2015-09-16 srm test for cancer treatment signal
US15/837,888 US20180195107A1 (en) 2013-03-15 2017-12-11 SRM Assay to Indicate Cancer Therapy
AU2018206787A AU2018206787A1 (en) 2013-03-15 2018-07-19 SRM assay to indicate cancer therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791833P 2013-03-15 2013-03-15
US61/791,833 2013-03-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/855,154 Continuation US9840728B2 (en) 2013-03-15 2015-09-15 SRM assay to indicate cancer therapy

Publications (2)

Publication Number Publication Date
WO2014146139A2 WO2014146139A2 (en) 2014-09-18
WO2014146139A3 true WO2014146139A3 (en) 2014-11-06

Family

ID=51538622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/031138 Ceased WO2014146139A2 (en) 2013-03-15 2014-03-18 Srm assay to indicate cancer therapy

Country Status (9)

Country Link
US (2) US9840728B2 (en)
EP (4) EP3470513B1 (en)
JP (4) JP6412100B2 (en)
KR (2) KR20180080342A (en)
CN (1) CN105229164B (en)
AU (2) AU2014232155B2 (en)
CA (2) CA2906965C (en)
IL (1) IL241631B (en)
WO (1) WO2014146139A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016122041A (en) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи NEW ANTI-CLAUDIN ANTIBODIES AND WAYS OF THEIR APPLICATION
US10078084B2 (en) * 2015-05-14 2018-09-18 Expression Pathology, Inc. SRM/MRM assay for the mesothelin (MSLN) protein
JP2018517136A (en) * 2015-05-14 2018-06-28 エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． SRM / MRM assay for fibroblast growth factor receptor 2 (FGFR2) protein
CA2986730C (en) * 2015-05-22 2020-04-14 Expression Pathology, Inc. Srm/mrm assay for the cyclin-dependent kinase inhibitor 2a (p16) protein
EP3328387B1 (en) * 2015-07-30 2020-07-22 Expression Pathology, Inc. Quantifying fr- and gart proteins for optimal cancer therapy
CA2999895A1 (en) 2015-09-24 2017-03-30 Expression Pathology, Inc. Quantifying met protein for cancer treatment
WO2017120376A1 (en) * 2016-01-05 2017-07-13 Expression Pathology, Inc. Quantifying protein for optimal cancer therapy
WO2017184905A1 (en) * 2016-04-20 2017-10-26 Expression Pathology, Inc. Method for improved hepatocellular cancer diagnosis
WO2018102827A1 (en) * 2016-12-04 2018-06-07 Expression Pathology, Inc. Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
CA3046202A1 (en) * 2016-12-06 2018-06-14 Expression Pathology, Inc. Improved methods of treating cancer by identification of patients sensitive to fgfr inhibitor therapy
US20210072255A1 (en) 2016-12-16 2021-03-11 The Brigham And Women's Hospital, Inc. System and method for protein corona sensor array for early detection of diseases
US20190353660A1 (en) * 2018-05-17 2019-11-21 Nantomics, Llc Identification of cancer patients sensitive or resistant to 5-fluorouracil (5-fu)
KR20260016611A (en) 2018-11-07 2026-02-03 시어 인코퍼레이티드 Compositions, methods and systems for protein corona analysis and uses thereof
FR3091524B1 (en) 2019-01-09 2021-10-29 Haulotte Group Lifting platform with removable control panel including anti-crushing protection for the operator
JP7518852B2 (en) 2019-03-26 2024-07-18 シアー， インコーポレイテッド Compositions, methods and systems for protein corona analysis from biological fluids and uses thereof
CN117169534A (en) 2019-08-05 2023-12-05 禧尔公司 Systems and methods for sample preparation, data generation and protein corona analysis
IL300826A (en) 2020-08-25 2023-04-01 Seer Inc Compositions and methods for assaying proteins and nucleic acids
EP4134451A1 (en) * 2021-08-11 2023-02-15 Universität zu Köln Method for identifying responsiveness to fibroblast growth factor receptor 1 inhibitor therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064422A1 (en) * 2001-11-29 2005-03-24 Barnidge David R Polypeptide quantitation
US20110281289A1 (en) * 2008-07-11 2011-11-17 Ludwig Institute For Cancer Research Ltd. Quantification of enzyme activity by mass spectrometry using immobilized substrates
US20120208824A1 (en) * 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
JP2012197258A (en) * 2011-03-23 2012-10-18 Tohoku Univ Method for quantitatively determining absolute mass of marker protein for individualized treatment and diagnosis
US20130011408A1 (en) * 2009-12-22 2013-01-10 Expression Pathology, Inc. Epidermal Growth Factor Receptor (EGFR) Protein SRM Assay

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501286B2 (en) 2002-08-14 2009-03-10 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US7632686B2 (en) 2002-10-03 2009-12-15 Anderson Forschung Group High sensitivity quantitation of peptides by mass spectrometry
DK1601450T3 (en) 2003-03-10 2013-09-08 Expression Pathology Inc Liquid tissue preparation from histopathologically processed biological samples, tissues and cells
WO2006127860A2 (en) * 2005-05-25 2006-11-30 Expression Pathology, Inc. Multiplex method for increased proteomic coverage from histopathologically processed biological samples using liquid tissue preparations
US8609345B2 (en) * 2005-05-25 2013-12-17 Expression Pathology Incorporated Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2006130527A2 (en) * 2005-05-31 2006-12-07 Novartis Ag Mutations and polymorphisms of fibroblast growth factor receptor 1
ES2458497T3 (en) * 2006-04-14 2014-05-05 Cell Signaling Technology, Inc. ALK gene and kinase mutant defects in solid human tumors
AU2007293280A1 (en) * 2006-09-07 2008-03-13 Astrazeneca Ab Method for evaluating patients for treatment with drugs targeting RET receptor tyrosine kinase
US8481497B2 (en) * 2007-05-29 2013-07-09 Sapporo Medical University Therapeutic agent for cancer, and method for treatment of cancer
WO2009002946A1 (en) * 2007-06-22 2008-12-31 Expression Pathology Method of discovering and analyzing secreted biomarkers of disease from solid tissue
EP2017622A1 (en) * 2007-07-19 2009-01-21 DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts Method for determining the concentration of a molecule
JP5769968B2 (en) * 2007-10-18 2015-08-26 セル・シグナリング・テクノロジー・インコーポレイテツド Translocation and mutant ROS kinase in human non-small cell lung cancer
WO2009054939A2 (en) * 2007-10-19 2009-04-30 Cell Signaling Technology, Inc. Cancer classification and methods of use
US20100267058A1 (en) * 2007-12-21 2010-10-21 Siemens Healthcare Diagnostics Inc. Circulating ret receptor
EP2124060A1 (en) * 2008-05-23 2009-11-25 ETH Zurich Method for high throughput peptide/protein assay generation and assays generated therewith
EP2193831A1 (en) * 2008-12-05 2010-06-09 Qiagen GmbH Parallel extraction of different biomolecules made of Formalin-fixed tissue
EP3266795A1 (en) * 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Method for detecting a fig-ros fusion polynucleotide
WO2011146945A2 (en) * 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
WO2012075318A2 (en) 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
JP6047502B2 (en) * 2010-12-27 2016-12-21 エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． cMET protein SRM / MRM assay
CA2823337C (en) * 2010-12-29 2019-09-10 Expression Pathology, Inc. Her3 protein srm/mrm assay
WO2012097276A2 (en) * 2011-01-13 2012-07-19 Expression Pathology, Inc. Bcl-2-like protein 11 srm/mrm assay
EA030462B1 (en) * 2011-05-16 2018-08-31 Дженентек, Инк. Fgfr1 agonists and methods of use thereof
CN103764676A (en) * 2011-08-04 2014-04-30 日本国立癌症研究中心 Fusion gene of KIF5B gene and RET gene, and method for determining effectiveness of cancer treatment targeting fusion gene

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064422A1 (en) * 2001-11-29 2005-03-24 Barnidge David R Polypeptide quantitation
US20120208824A1 (en) * 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US20110281289A1 (en) * 2008-07-11 2011-11-17 Ludwig Institute For Cancer Research Ltd. Quantification of enzyme activity by mass spectrometry using immobilized substrates
US20130011408A1 (en) * 2009-12-22 2013-01-10 Expression Pathology, Inc. Epidermal Growth Factor Receptor (EGFR) Protein SRM Assay
JP2012197258A (en) * 2011-03-23 2012-10-18 Tohoku Univ Method for quantitatively determining absolute mass of marker protein for individualized treatment and diagnosis

Also Published As

Publication number Publication date
JP2016519287A (en) 2016-06-30
EP3470513A1 (en) 2019-04-17
JP2019053064A (en) 2019-04-04
AU2014232155A1 (en) 2015-11-05
JP2019053065A (en) 2019-04-04
CN105229164B (en) 2019-02-12
US20180195107A1 (en) 2018-07-12
AU2018206787A1 (en) 2018-08-09
JP6668432B2 (en) 2020-03-18
US9840728B2 (en) 2017-12-12
EP2984176A4 (en) 2017-04-26
IL241631B (en) 2018-11-29
EP3474014B1 (en) 2020-06-17
EP3470845B1 (en) 2020-05-13
KR20160002762A (en) 2016-01-08
KR101874501B1 (en) 2018-07-05
CA2906965C (en) 2018-07-31
WO2014146139A2 (en) 2014-09-18
CA2906965A1 (en) 2014-09-18
US20150376678A1 (en) 2015-12-31
EP3470513B1 (en) 2020-05-13
CA3009552A1 (en) 2014-09-18
JP6412100B2 (en) 2018-10-24
CN105229164A (en) 2016-01-06
JP6672411B2 (en) 2020-03-25
EP2984176A2 (en) 2016-02-17
KR20180080342A (en) 2018-07-11
EP2984176B1 (en) 2018-12-05
JP6596555B2 (en) 2019-10-23
AU2014232155B2 (en) 2018-05-24
EP3474014A1 (en) 2019-04-24
EP3470845A1 (en) 2019-04-17
JP2019049557A (en) 2019-03-28

Similar Documents

Publication Publication Date Title
WO2014146139A3 (en) Srm assay to indicate cancer therapy
HK1208284A1 (en) Deep-maldi tof mass spectrometry of complex biological samples, e.g., serum, and uses thereof
MX2017000083A (en) Platinum compounds, compositions, and uses thereof.
WO2016130704A3 (en) Methods and compositions for analyzing cellular components
EP4242304A3 (en) Methods and reagents for analyzing protein-protein interfaces
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
WO2016004233A3 (en) Srm assays to chemotherapy targets
WO2011047087A3 (en) Protein detection via nanoreporters
EP4667583A3 (en) Multiple tagging of long dna fragments
EP4297036A3 (en) Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex
WO2018072862A8 (en) Method for evaluating data from mass spectrometry, mass spectrometry method, and maldi-tof mass spectrometer
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
MX2021001418A (en) Production of heteromultimeric proteins using mammalian cells.
WO2012119004A3 (en) Parathyroid hormone analogs, compositions and uses thereof
EP3309169A4 (en) Antibody binding specifically to isolated vimentin-derived peptide, or binding fragment of the peptide
Jabbour et al. Mass spectrometry-based proteomics techniques for biological identification
NZ731491A (en) Cd83 binding proteins and uses thereof
WO2013044265A3 (en) Multiplex mrm assay for evaluation of cancer
EP3186272A4 (en) Functionalized beta-sheet peptide stabilized membrane proteins, constructs comprising same, and methods of forming and using same
EP4220178A3 (en) Quantitation of tamoxifen and metabolites thereof by mass spectrometry
WO2015103645A3 (en) Srm assay for pd-l1
WO2015068075A3 (en) Detection of tau
EP3888671A3 (en) Protein formulations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480021231.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14763214

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2906965

Country of ref document: CA

Ref document number: 2016502614

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 241631

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 20157028737

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014763214

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014232155

Country of ref document: AU

Date of ref document: 20140318

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14763214

Country of ref document: EP

Kind code of ref document: A2